- Home
- IONS
as 04-18-2025 1:38pm EST
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 4.6B | IPO Year: | 1991 |
| Target Price: | $57.00 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.95 - $52.34 | Next Earning Date: | 04-30-2025 |
| Revenue: | $705,138,000 | Revenue Growth: | -10.47% |
| Revenue Growth (this year): | -3.51% | Revenue Growth (next year): | 25.80% |
Stock Insider Trading Activity of Ionis Pharmaceuticals Inc. (IONS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Baroldi Joseph | IONS | EVP, Chief Business Officer | Apr 15 '25 | Sell | $28.40 | 3,928 | $111,555.20 | 31,926 | |
| Birchler Brian | IONS | EVP, Corp and Development Ops | Apr 15 '25 | Sell | $28.37 | 680 | $19,291.60 | 56,660 | |
| Monia Brett P | IONS | Chief Executive Officer | Mar 11 '25 | Sell | $32.32 | 140 | $4,524.80 | 180,980 | |
| O'NEIL PATRICK R. | IONS | EVP CLO & General Counsel | Feb 20 '25 | Sell | $32.35 | 1,207 | $39,046.45 | 56,245 | |
| Monia Brett P | IONS | Chief Executive Officer | Feb 4 '25 | Sell | $31.65 | 38,843 | $1,229,462.52 | 180,980 | |
| O'NEIL PATRICK R. | IONS | EVP CLO & General Counsel | Feb 4 '25 | Sell | $31.62 | 6,165 | $194,939.15 | 56,245 | |
| Swayze Eric | IONS | EVP Research | Jan 30 '25 | Sell | $32.31 | 1,367 | $44,162.03 | 48,017 | |
| Monia Brett P | IONS | Chief Executive Officer | Jan 30 '25 | Sell | $32.45 | 13,242 | $429,655.23 | 180,980 | |
| Schneider Eugene | IONS | EVP, Chf Clinical Develop Ofcr | Jan 30 '25 | Sell | $32.20 | 1,484 | $47,779.90 | 61,056 | |
| BENNETT C FRANK | IONS | EVP, Chief Scientific Officer | Jan 30 '25 | Sell | $32.46 | 1,327 | $43,079.20 | 93,146 |
Latest Ionis Pharmaceuticals Inc. News
IONS Breaking Stock News: Dive into IONS Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
Ionis to hold first quarter 2025 financial results webcast
Zacks
9 days ago
Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains?
MT Newswires
12 days ago
HC Wainwright Initiates Ionis Pharmaceuticals With Buy Rating, $45 Price Target
Business Wire
16 days ago
Ionis to host expert panel discussion on sHTG
MT Newswires
19 days ago
Redburn Atlantic Initiates Ionis Pharmaceuticals at Neutral With $39 Price Target
Business Wire
19 days ago
Ionis to present at upcoming investor conferences
Zacks
22 days ago
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?
Pharmaceutical Technology
23 days ago
Ionis and Sobi agree on olezarsen commercialisation
Compare IONS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IONS Ionis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.